Cefpirome sulfate is a new injectable cephalosporin indicated for the treatment of
severe urinary and respiratory tract infections, including septicemia and nosocomial
infections. Cefpirome sulfate is reported to be the first true fourth-generation
cephalosporin due to its similar activities to third-generation antibiotics against
Gram-positive bacteria and to first-generation antibiotics against Gram-negative
bacteria. Its efficacy against P.aeruginosa is comparable to ceftazidime. The broad
spectrum of activity includes Klebsiella, methicillin-sensitive staphylococci,
penicillin-resistant pneumococci, E.coli which generates extended-spectrum
beta-lactamases and multi-resistant organisms such as Citrobacter, Enterobacter and
Serratia.
